The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biogen Inc

Nasdaq: BIIB
Last

(U.S.) $263.86

Today's change-9.41 -3.44%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Biogen Inc

Nasdaq: BIIB
Last

(U.S.) $263.86

Today's change-9.41 -3.44%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Biogen Inc crosses below 20-day moving average

Biogen Inc closed sharply lower Friday, dropping (U.S.)$9.41 or 3.44% to (U.S.)$263.86 and crossing below its 20-day moving average. Over the last five days, shares have lost 3.37% and sit 3.88% above their 52-week low. This security has underperformed the S&P 500 by 25.48% during the last year.

Key company metrics

  • Open(U.S.) $271.10
  • Previous close(U.S.) $273.27
  • High(U.S.) $272.67
  • Low(U.S.) $258.46
  • Bid / Ask-- / --
  • YTD % change-13.87%
  • Volume2,856,944
  • Average volume (10-day)2,555,220
  • Average volume (1-month)1,995,216
  • Average volume (3-month)2,413,898
  • 52-week range(U.S.) $254.00 to (U.S.) $480.18
  • Beta0.98
  • Trailing P/E17.20×
  • P/E 1 year forward14.16×
  • Forward PEG1.51×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $15.34
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+33.50%

Based on its net profit margin of 33.50%, Biogen Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue2,8392,7782,5922,555
Total other revenue--------
Total revenue2,8392,7782,5922,555
Gross profit2,5082,4682,3062,243
Total cost of revenue332310286312
Total operating expense1,6711,4061,3591,437
Selling / general / administrative583478492560
Research & development542520491461
Depreciation / amortization97989296
Interest expense (income), net operating--------
Unusual expense (income)1180-28
Other operating expenses, total--------
Operating income1,1681,3721,2331,118
Interest income (expense), net non-operating-67-16-6-7
Gain (loss) on sale of assets--------
Other--------
Income before tax1,0861,3561,2221,103
Income after tax8291,026930821
Income tax, total257330293282
Net income832966927823
Total adjustments to net income--------
Net income before extra. items832966927823
Minority interest3-5422
Equity in affiliates0-7-5-1
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items832966927823
Inc. avail. to common incl. extra. items832966927823
Diluted net income832966927823
Dilution adjustment--------
Diluted weighted average shares221233236236
Diluted EPS excluding extraordinary itemsvalue per share3.774.153.933.49
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share4.174.153.933.52